Latest Acquisition News

Netwealth Group Limited reported a standout FY2025 with net profit rising nearly 40% and funds under administration climbing 28%, underpinning a 37.5% increase in dividends. Strategic fintech acquisitions and robust governance enhancements position the company for sustained growth.

Qube Holdings Limited reported robust FY25 underlying revenue growth of 27%, driven by strong performances in its Logistics & Infrastructure and Ports & Bulk divisions, while declaring a 71% increase in full-year dividends. Despite challenges including industrial action and weather disruptions, Qube expects continued earnings growth in FY26 supported by strategic acquisitions and operational resilience.

Megaport Limited delivered a robust FY25 with 20% growth in annual recurring revenue and EBITDA surpassing guidance, setting the stage for continued expansion in FY26.

EQT Holdings Limited reported a robust FY25 with a 60% jump in net profit and record funds under management, while completing a major acquisition integration and raising dividends.

Sipa Resources has completed a key heritage survey at its Crown Gold Project near Kalgoorlie, clearing the way for initial drilling expected to begin next month. Meanwhile, assay results from its maiden drilling in South Australia are imminent.

Ridley Corporation reported solid FY25 results with EBITDA up 8.6% to $97.8 million and NPAT rising 8.7% to $43.3 million, underpinned by strategic acquisitions and disciplined capital management.

Redox Limited reported a 9.4% increase in FY25 revenue to $1.244 billion driven by volume growth and strategic acquisitions, while profits declined amid inflationary pressures. The company declared a final dividend of 6.5 cents per share and maintains zero net debt.

Ridley Corporation Limited reported a solid FY25 with revenue up 3.1% to $1.3 billion and net profit after tax rising 8.7% to $43.3 million. The company declared a fully franked final dividend of 5.00 cents per share, signaling confidence in its diversified growth strategy.

Telix Pharmaceuticals reported a robust 63% year-over-year revenue increase in H1 2025, driven by strong sales of its precision medicine products and strategic acquisitions. The company is advancing multiple late-stage clinical trials and expanding its global manufacturing footprint.

Redox Ltd reported a robust 9.4% increase in revenue for FY25, supported by strong volume growth and three strategic acquisitions, despite margin compression and a challenging macroeconomic backdrop.

Telix Pharmaceuticals reported a robust 63% revenue increase in H1 2025, driven by commercial growth and strategic investments, while advancing key clinical trials and maintaining full-year guidance.

Telix Pharmaceuticals reported a robust 63% increase in revenue to $390.4 million for the first half of 2025, driven by strong Illuccix sales and the acquisition of RLS Radiopharmacies. Despite this growth, the company recorded a net loss of $2.3 million, reflecting increased investments and finance costs.